Table 2.
Population characteristics during study interventions
| Characteristics | Study visit 1 (before vitamin D3 intervention) | Study visit 2 (after vitamin D3 intervention) |
|---|---|---|
| n | 14 | |
| Demographic variables | ||
| Weight (kg) | 102.9 ± 3.3 | 103.4 ± 3.3 |
| Body mass index (kg/m2) | 36.3 ± 1.2 | 36.3 ± 1.3 |
| Serum creatinine (mg/dl) | 0.90 ± 0.1 | 0.92 ± 0.1 |
| Calcium regulatory variables | ||
| 25(OH)D (ng/ml) | 18.2 ± 1.8 | 51.9 ± 3.1a |
| 1,25(OH)2D (pg/ml) | 38.1 ± 3.3 | 57.7 ± 4.5a |
| PTH (pg/ml) | 46.4 ± 4.3 | 37.1 ± 3.1b |
| Serum calcium (mg/dl)c | 8.9 ± 0.1 | 9.1 ± 0.8d |
| 24-h urine variables | ||
| Urine creatinine (mg) | 1599.5 ± 103.4 | 1692.6 ± 131.8 |
| Urine sodium (mmol) | 343.5 ± 37.1 | 339.0 ± 34.8 |
| Urine potassium (mmol) | 95.0 ± 8.3 | 91.5 ± 8.0 |
| Urine calcium (mg/kg) | 1.9 ± 0.3 | 2.2 ± 0.2 |
| Urine albumin (mg) | 8.2 ± 1.4 | 11.0 ± 2.7 |
| Urinary calcium (mg) to creatinine (mg) ratio | 0.12 ± 0.0 | 0.14 ± 0.0 |
| Sodium regulatory variables | ||
| NT-pro-BNP (pg/ml) | 92.4 ± 38.9 | 56.4 ± 16.1 |
| PRA (ng/ml · h) | 0.21 ± 0.0 | 0.26 ± 0.1 |
| Aldosterone (ng/dl) | 3.3 ± 0.2 | 3.7 ± 0.4 |
| 24-h aldosterone excretion rate (μg/d) | 6.5 ± 1.4 | 5.8 ± 1.8 |
Baseline study visit demographics and laboratory data were obtained after medication washout and completion of the study diet. Data are presented as means ± sem.
a
P < 0.0001
b
P < 0.01.
c
Normal range is 8.7–10.2 mg/dl.
d
P < 0.05.